Management of thalassemia (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Management of thalassemia" in English language version.

refsWebsite

Global rank English rank

36nih.gov

4^th place

26doi.org

2^nd place

11web.archive.org

1^st place

9semanticscholar.org

11^th place

8^th place

4fda.gov

447^th place

338^th place

2hematologylibrary.org

low place

2harvard.edu

18^th place

17^th place

2businesswire.com

615^th place

407^th place

1medscape.com

719^th place

636^th place

1ascpjournals.org

low place

1jbc.org

4,455^th place

5,199^th place

1haematologica.org

low place

1indiatimes.com

17^th place

15^th place

1europa.eu

68^th place

117^th place

1npr.org

92^nd place

72^nd place

1gov.uk

432^nd place

278^th place

1nature.com

234^th place

397^th place

ascpjournals.org

ajcp.ascpjournals.org

Claude Owen Burdick. "Separating Thalassemia Trait and Iron Deficiency by Simple Inspection". American Society for Clinical Pathology. Archived from the original on 22 September 2014. Retrieved 27 September 2011.

businesswire.com

"Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, Casgevy (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia" (Press release). Vertex Pharmaceuticals. 16 November 2023. Archived from the original on 22 November 2023. Retrieved 9 December 2023 – via Business Wire.
"Vertex and CRISPR Therapeutics Announce US FDA Approval of Casgevy (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease" (Press release). Vertex Pharmaceuticals. 8 December 2023. Archived from the original on 9 December 2023. Retrieved 9 December 2023 – via Business Wire.

doi.org

Sharma, A; Easow Mathew, M; Puri, L (17 September 2019). "Splenectomy for people with thalassaemia major or intermedia". The Cochrane Database of Systematic Reviews. 2019 (9): CD010517. doi:10.1002/14651858.CD010517.pub3. PMC 6746994. PMID 31529486.
Aisen P, Leibman A, Zweier J; Leibman; Zweier (March 1978). "Stoichiometric and site characteristics of the binding of iron to human transferrin". J. Biol. Chem. 253 (6): 1930–7. doi:10.1016/S0021-9258(19)62337-9. PMID 204636.{{cite journal}}: CS1 maint: multiple names: authors list (link)
Brittenham, Gary M.; Griffith, Patricia M.; Nienhuis, Arthur W.; McLaren, Christine E.; Young, Neal S.; Tucker, Eben E.; Allen, Christopher J.; Farrell, David E.; Harris, John W. (1994). "Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia Major". New England Journal of Medicine. 331 (9): 567–73. doi:10.1056/NEJM199409013310902. PMID 8047080.
Cozar, O.; Leopold, N.; Jelic, C.; Chiş, V.; David, L.; Mocanu, A.; Tomoaia-Cotişel, M. (2006). "IR, Raman and surface-enhanced Raman study of desferrioxamine B and its Fe(III) complex, ferrioxamine B". Journal of Molecular Structure. 788 (1–3): 1–6. Bibcode:2006JMoSt.788....1C. doi:10.1016/j.molstruc.2005.04.035.
Cohen, Alan; Martin, Marie; Schwartz, Elias (1981). "Response to long-term deferoxamine therapy in thalassemia". The Journal of Pediatrics. 99 (5): 689–94. doi:10.1016/S0022-3476(81)80385-X. PMID 7299539.
Pennell, D. J.; Berdoukas, V; Karagiorga, M; Ladis, V; Piga, A; Aessopos, A; Gotsis, ED; Tanner, MA; et al. (2006). "Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis". Blood. 107 (9): 3738–44. doi:10.1182/blood-2005-07-2948. PMID 16352815. S2CID 6802958.
Jin, Haiyan; Terai, Shuji; Sakaida, Isao (2007). "The iron chelator deferoxamine causes activated hepatic stellate cells to become quiescent and to undergo apoptosis". Journal of Gastroenterology. 42 (6): 475–84. doi:10.1007/s00535-007-2020-5. PMID 17671763. S2CID 34700148.
Kaye, Todd B.; Guay, André T.; Simonson, Donald C. (1993). "Non-insulin-dependent diabetes mellitus and elevated serum ferritin level". Journal of Diabetes and Its Complications. 7 (4): 245–249. doi:10.1016/S0002-9610(05)80252-1. PMID 8219368.
Olivieri, Nancy F.; Koren, Gideon; Harris, Jonathan; Khattak, Sohail; Freedman, Melvin H.; Templeton, Douglas M.; Bailey, John D.; Reilly, B. J. (1992). "Growth Failure and Bony Changes Induced by Deferoxamine". Journal of Pediatric Hematology/Oncology. 14 (1): 48–56. doi:10.1097/00043426-199221000-00007. PMID 1550263.
Kattamis, Antonis (2005). "Combined therapy with deferoxamine and deferiprone". Annals of the New York Academy of Sciences. 1054 (1): 175–82. Bibcode:2005NYASA1054..175K. doi:10.1196/annals.1345.020. PMID 16339663. S2CID 29566007.
Wiwanitkit, Viroj (2006). "Quantum chemical analysis of the deferiprone-iron binding reaction". International Journal of Nanomedicine. 1 (1): 111–3. doi:10.2147/nano.2006.1.1.111. PMC 2426763. PMID 17722270.
Olivieri, Nancy F.; Brittenham, Gary M. (1997). "Iron-Chelating Therapy and the Treatment of Thalassemia". Blood. 89 (3): 739–61. doi:10.1182/blood.V89.3.739. PMID 9028304.
Galanello, R.; Campus, S. (2009). "Deferiprone Chelation Therapy for Thalassemia Major". Acta Haematologica. 122 (2–3): 155–64. doi:10.1159/000243800. PMID 19907153. S2CID 31161087.
Wiwanitkit, Viroj (2006). "Quantum Chemical Analysis of the Deferiprone-Iron Binding Reaction". International Journal of Nanomedicine. 1 (1): 111–3. doi:10.2147/nano.2006.1.1.111. PMC 2426763. PMID 17722270.
Heli, Hossein; Mirtorabi, Siamak; Karimian, Khashayar (2011). "Advances in iron chelation: An update". Expert Opinion on Therapeutic Patents. 21 (6): 819–56. doi:10.1517/13543776.2011.569493. PMID 21449664. S2CID 41639654.
Cappellini, M. D.; Cohen, A; Piga, A; Bejaoui, M; Perrotta, S; Agaoglu, L; Aydinok, Y; Kattamis, A; et al. (2006). "A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia". Blood. 107 (9): 3455–62. doi:10.1182/blood-2005-08-3430. PMID 16352812.
Nisbet-Brown, Eric; Olivieri, Nancy F; Giardina, Patricia J; Grady, Robert W; Neufeld, Ellis J; Séchaud, Romain; Krebs-Brown, Axel J; Anderson, Judith R; et al. (2003). "Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: A randomised, double-blind, placebo-controlled, dose-escalation trial". The Lancet. 361 (9369): 1597–602. doi:10.1016/S0140-6736(03)13309-0. PMID 12747879. S2CID 12396225.
Cappellini, M. D.; Bejaoui, M.; Agaoglu, L.; Canatan, D.; Capra, M.; Cohen, A.; Drelichman, G.; Economou, M.; et al. (2011). "Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: Efficacy and safety during 5 years' follow-up". Blood. 118 (4): 884–93. doi:10.1182/blood-2010-11-316646. PMID 21628399.
Tesoriere, L.; Allegra, M.; Butera, D.; Gentile, C.; Livrea, M. A. (2006). "Cytoprotective effects of the antioxidant phytochemical indicaxanthin in β-thalassemia red blood cells". Free Radical Research. 40 (7): 753–61. doi:10.1080/10715760600554228. PMID 16984002. S2CID 25837703.
Leung TN, Lau TK, Chung TKh; Lau; Chung (April 2005). "Thalassaemia screening in pregnancy". Current Opinion in Obstetrics and Gynecology. 17 (2): 129–34. doi:10.1097/01.gco.0000162180.22984.a3. PMID 15758603. S2CID 41877258.{{cite journal}}: CS1 maint: multiple names: authors list (link)
Samavat A, Modell B; Modell (November 2004). "Iranian national thalassaemia screening programme". BMJ (Clinical Research Ed.). 329 (7475): 1134–7. doi:10.1136/bmj.329.7475.1134. PMC 527686. PMID 15539666.
Sabloff, M; Chandy, M; Wang, Z; Logan, BR; Ghavamzadeh, A; Li, CK; Irfan, SM; Bredeson, CN; et al. (2011). "HLA-matched sibling bone marrow transplantation for β-thalassemia major". Blood. 117 (5): 1745–50. doi:10.1182/blood-2010-09-306829. PMC 3056598. PMID 21119108.
Sodani, P; Isgrò, A; Gaziev, J; Paciaroni, K; Marziali, M; Simone, MD; Roveda, A; De Angelis, G; et al. (2011). "T cell-depleted hla-haploidentical stem cell transplantation in thalassemia young patients". Pediatric Reports. 3 (Suppl 2): e13. doi:10.4081/pr.2011.s2.e13. PMC 3206538. PMID 22053275.
Negre, Olivier; Eggimann, Anne-Virginie; Beuzard, Yves; Ribeil, Jean-Antoine; Bourget, Philippe; Borwornpinyo, Suparerk; Hongeng, Suradej; Hacein-Bey, Salima; Cavazzana, Marina; Leboulch, Philippe; Payen, Emmanuel (February 2016). "Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the β – Gene". Human Gene Therapy. 27 (2): 148–165. doi:10.1089/hum.2016.007. PMC 4779296. PMID 26886832.
Biffi, A (19 April 2018). "Gene Therapy as a Curative Option for β-Thalassemia". The New England Journal of Medicine. 378 (16): 1551–1552. doi:10.1056/NEJMe1802169. PMID 29669229.
Sheridan C (November 2023). "The world's first CRISPR therapy is approved: who will receive it?". Nature Biotechnology. 42 (1): 3–4. doi:10.1038/d41587-023-00016-6. PMID 37989785. S2CID 265350318. Archived from the original on 4 December 2023. Retrieved 4 December 2023.

europa.eu

ema.europa.eu

"Zynteglo EPAR". European Medicines Agency (EMA). 25 March 2019. Archived from the original on 16 August 2019. Retrieved 16 August 2019. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

fda.gov

"Zynteglo". U.S. Food and Drug Administration. 17 August 2022. Archived from the original on 26 August 2022. Retrieved 26 August 2022.
"FDA Approves First Cell-Based Gene Therapy to Treat Adult and Pediatric Patients with Beta-thalassemia Who Require Regular Blood Transfusions". U.S. Food and Drug Administration (FDA) (Press release). 17 August 2022. Archived from the original on 21 August 2022. Retrieved 20 August 2022. This article incorporates text from this source, which is in the public domain.
"FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease". U.S. Food and Drug Administration (FDA). 8 December 2023. Archived from the original on 8 December 2023. Retrieved 8 December 2023. This article incorporates text from this source, which is in the public domain.
Commissioner, Office of the (2024-01-16). "FDA Roundup: January 16, 2024". FDA. Retrieved 2024-01-19.

gov.uk

"MHRA authorises world-first gene therapy that aims to cure sickle-cell disease and transfusion-dependent β-thalassemia". Medicines and Healthcare products Regulatory Agency (MHRA) (Press release). 16 November 2023. Archived from the original on 25 November 2023. Retrieved 8 December 2023.

haematologica.org

R Galanello; Piga, A; Forni, GL; Bertrand, Y; Foschini, ML; Bordone, E; Leoni, G; Lavagetto, A; et al. (2006-01-01). "Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with β-thalassemia major". Haematologica. 91 (10): 1343–51. PMID 17018383.

harvard.edu

ui.adsabs.harvard.edu

Cozar, O.; Leopold, N.; Jelic, C.; Chiş, V.; David, L.; Mocanu, A.; Tomoaia-Cotişel, M. (2006). "IR, Raman and surface-enhanced Raman study of desferrioxamine B and its Fe(III) complex, ferrioxamine B". Journal of Molecular Structure. 788 (1–3): 1–6. Bibcode:2006JMoSt.788....1C. doi:10.1016/j.molstruc.2005.04.035.
Kattamis, Antonis (2005). "Combined therapy with deferoxamine and deferiprone". Annals of the New York Academy of Sciences. 1054 (1): 175–82. Bibcode:2005NYASA1054..175K. doi:10.1196/annals.1345.020. PMID 16339663. S2CID 29566007.

hematologylibrary.org

bloodjournal.hematologylibrary.org

Brittenham, Gary M; Olivieri, Nancy F (1997). "Iron-chelating therapy and the treatment of thalassemia". Journal of the American Society of Hematology. 89 (3): 739–761. PMID 9028304. Retrieved 28 February 2013.
Olivieri, Nancy F.; Brittenham, Gary M. (1997). "Iron-Chelating Therapy and the Treatment of Thalassemia". Blood. 89 (3): 739–61. doi:10.1182/blood.V89.3.739. PMID 9028304.

indiatimes.com

timesofindia.indiatimes.com

His sister's keeper: Brother's blood is boon of life, Times of India, 17 September 2009

jbc.org

Aisen P, Leibman A, Zweier J; Leibman; Zweier (March 1978). "Stoichiometric and site characteristics of the binding of iron to human transferrin". J. Biol. Chem. 253 (6): 1930–7. doi:10.1016/S0021-9258(19)62337-9. PMID 204636.{{cite journal}}: CS1 maint: multiple names: authors list (link)

medscape.com

emedicine.medscape.com

"Pediatric Thalassemia Treatment & Management". Medical Care. Open Publishing. 30 April 2010. Retrieved 27 September 2011.

nature.com

Sheridan C (November 2023). "The world's first CRISPR therapy is approved: who will receive it?". Nature Biotechnology. 42 (1): 3–4. doi:10.1038/d41587-023-00016-6. PMID 37989785. S2CID 265350318. Archived from the original on 4 December 2023. Retrieved 4 December 2023.

nih.gov

pubmed.ncbi.nlm.nih.gov

Sharma, A; Easow Mathew, M; Puri, L (17 September 2019). "Splenectomy for people with thalassaemia major or intermedia". The Cochrane Database of Systematic Reviews. 2019 (9): CD010517. doi:10.1002/14651858.CD010517.pub3. PMC 6746994. PMID 31529486.
Aisen P, Leibman A, Zweier J; Leibman; Zweier (March 1978). "Stoichiometric and site characteristics of the binding of iron to human transferrin". J. Biol. Chem. 253 (6): 1930–7. doi:10.1016/S0021-9258(19)62337-9. PMID 204636.{{cite journal}}: CS1 maint: multiple names: authors list (link)
Brittenham, Gary M; Olivieri, Nancy F (1997). "Iron-chelating therapy and the treatment of thalassemia". Journal of the American Society of Hematology. 89 (3): 739–761. PMID 9028304. Retrieved 28 February 2013.
Brittenham, Gary M.; Griffith, Patricia M.; Nienhuis, Arthur W.; McLaren, Christine E.; Young, Neal S.; Tucker, Eben E.; Allen, Christopher J.; Farrell, David E.; Harris, John W. (1994). "Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia Major". New England Journal of Medicine. 331 (9): 567–73. doi:10.1056/NEJM199409013310902. PMID 8047080.
Cohen, Alan; Martin, Marie; Schwartz, Elias (1981). "Response to long-term deferoxamine therapy in thalassemia". The Journal of Pediatrics. 99 (5): 689–94. doi:10.1016/S0022-3476(81)80385-X. PMID 7299539.
Pennell, D. J.; Berdoukas, V; Karagiorga, M; Ladis, V; Piga, A; Aessopos, A; Gotsis, ED; Tanner, MA; et al. (2006). "Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis". Blood. 107 (9): 3738–44. doi:10.1182/blood-2005-07-2948. PMID 16352815. S2CID 6802958.
Jin, Haiyan; Terai, Shuji; Sakaida, Isao (2007). "The iron chelator deferoxamine causes activated hepatic stellate cells to become quiescent and to undergo apoptosis". Journal of Gastroenterology. 42 (6): 475–84. doi:10.1007/s00535-007-2020-5. PMID 17671763. S2CID 34700148.
Kaye, Todd B.; Guay, André T.; Simonson, Donald C. (1993). "Non-insulin-dependent diabetes mellitus and elevated serum ferritin level". Journal of Diabetes and Its Complications. 7 (4): 245–249. doi:10.1016/S0002-9610(05)80252-1. PMID 8219368.
Olivieri, Nancy F.; Koren, Gideon; Harris, Jonathan; Khattak, Sohail; Freedman, Melvin H.; Templeton, Douglas M.; Bailey, John D.; Reilly, B. J. (1992). "Growth Failure and Bony Changes Induced by Deferoxamine". Journal of Pediatric Hematology/Oncology. 14 (1): 48–56. doi:10.1097/00043426-199221000-00007. PMID 1550263.
Ambruso, DR; Mahony, BS; Githens, JH; Rhoades, ED (1982). "Effect of subcutaneous deferoxamine and oral vitamin C on iron excretion in congenital hypoplastic anemia and refractory anemia associated with the 5q-syndrome". The American Journal of Pediatric Hematology/Oncology. 4 (2): 115–23. PMID 7114394.
Kattamis, Antonis (2005). "Combined therapy with deferoxamine and deferiprone". Annals of the New York Academy of Sciences. 1054 (1): 175–82. Bibcode:2005NYASA1054..175K. doi:10.1196/annals.1345.020. PMID 16339663. S2CID 29566007.
Wiwanitkit, Viroj (2006). "Quantum chemical analysis of the deferiprone-iron binding reaction". International Journal of Nanomedicine. 1 (1): 111–3. doi:10.2147/nano.2006.1.1.111. PMC 2426763. PMID 17722270.
Olivieri, Nancy F.; Brittenham, Gary M. (1997). "Iron-Chelating Therapy and the Treatment of Thalassemia". Blood. 89 (3): 739–61. doi:10.1182/blood.V89.3.739. PMID 9028304.
Galanello, R.; Campus, S. (2009). "Deferiprone Chelation Therapy for Thalassemia Major". Acta Haematologica. 122 (2–3): 155–64. doi:10.1159/000243800. PMID 19907153. S2CID 31161087.
Wiwanitkit, Viroj (2006). "Quantum Chemical Analysis of the Deferiprone-Iron Binding Reaction". International Journal of Nanomedicine. 1 (1): 111–3. doi:10.2147/nano.2006.1.1.111. PMC 2426763. PMID 17722270.
Heli, Hossein; Mirtorabi, Siamak; Karimian, Khashayar (2011). "Advances in iron chelation: An update". Expert Opinion on Therapeutic Patents. 21 (6): 819–56. doi:10.1517/13543776.2011.569493. PMID 21449664. S2CID 41639654.
Cappellini, M. D.; Cohen, A; Piga, A; Bejaoui, M; Perrotta, S; Agaoglu, L; Aydinok, Y; Kattamis, A; et al. (2006). "A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia". Blood. 107 (9): 3455–62. doi:10.1182/blood-2005-08-3430. PMID 16352812.
R Galanello; Piga, A; Forni, GL; Bertrand, Y; Foschini, ML; Bordone, E; Leoni, G; Lavagetto, A; et al. (2006-01-01). "Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with β-thalassemia major". Haematologica. 91 (10): 1343–51. PMID 17018383.
Nisbet-Brown, Eric; Olivieri, Nancy F; Giardina, Patricia J; Grady, Robert W; Neufeld, Ellis J; Séchaud, Romain; Krebs-Brown, Axel J; Anderson, Judith R; et al. (2003). "Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: A randomised, double-blind, placebo-controlled, dose-escalation trial". The Lancet. 361 (9369): 1597–602. doi:10.1016/S0140-6736(03)13309-0. PMID 12747879. S2CID 12396225.
Cappellini, M. D.; Bejaoui, M.; Agaoglu, L.; Canatan, D.; Capra, M.; Cohen, A.; Drelichman, G.; Economou, M.; et al. (2011). "Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: Efficacy and safety during 5 years' follow-up". Blood. 118 (4): 884–93. doi:10.1182/blood-2010-11-316646. PMID 21628399.
Tesoriere, L.; Allegra, M.; Butera, D.; Gentile, C.; Livrea, M. A. (2006). "Cytoprotective effects of the antioxidant phytochemical indicaxanthin in β-thalassemia red blood cells". Free Radical Research. 40 (7): 753–61. doi:10.1080/10715760600554228. PMID 16984002. S2CID 25837703.
Leung TN, Lau TK, Chung TKh; Lau; Chung (April 2005). "Thalassaemia screening in pregnancy". Current Opinion in Obstetrics and Gynecology. 17 (2): 129–34. doi:10.1097/01.gco.0000162180.22984.a3. PMID 15758603. S2CID 41877258.{{cite journal}}: CS1 maint: multiple names: authors list (link)
Samavat A, Modell B; Modell (November 2004). "Iranian national thalassaemia screening programme". BMJ (Clinical Research Ed.). 329 (7475): 1134–7. doi:10.1136/bmj.329.7475.1134. PMC 527686. PMID 15539666.
Sabloff, M; Chandy, M; Wang, Z; Logan, BR; Ghavamzadeh, A; Li, CK; Irfan, SM; Bredeson, CN; et al. (2011). "HLA-matched sibling bone marrow transplantation for β-thalassemia major". Blood. 117 (5): 1745–50. doi:10.1182/blood-2010-09-306829. PMC 3056598. PMID 21119108.
Sodani, P; Isgrò, A; Gaziev, J; Paciaroni, K; Marziali, M; Simone, MD; Roveda, A; De Angelis, G; et al. (2011). "T cell-depleted hla-haploidentical stem cell transplantation in thalassemia young patients". Pediatric Reports. 3 (Suppl 2): e13. doi:10.4081/pr.2011.s2.e13. PMC 3206538. PMID 22053275.
Negre, Olivier; Eggimann, Anne-Virginie; Beuzard, Yves; Ribeil, Jean-Antoine; Bourget, Philippe; Borwornpinyo, Suparerk; Hongeng, Suradej; Hacein-Bey, Salima; Cavazzana, Marina; Leboulch, Philippe; Payen, Emmanuel (February 2016). "Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the β – Gene". Human Gene Therapy. 27 (2): 148–165. doi:10.1089/hum.2016.007. PMC 4779296. PMID 26886832.
Biffi, A (19 April 2018). "Gene Therapy as a Curative Option for β-Thalassemia". The New England Journal of Medicine. 378 (16): 1551–1552. doi:10.1056/NEJMe1802169. PMID 29669229.
Sheridan C (November 2023). "The world's first CRISPR therapy is approved: who will receive it?". Nature Biotechnology. 42 (1): 3–4. doi:10.1038/d41587-023-00016-6. PMID 37989785. S2CID 265350318. Archived from the original on 4 December 2023. Retrieved 4 December 2023.

ncbi.nlm.nih.gov

Sharma, A; Easow Mathew, M; Puri, L (17 September 2019). "Splenectomy for people with thalassaemia major or intermedia". The Cochrane Database of Systematic Reviews. 2019 (9): CD010517. doi:10.1002/14651858.CD010517.pub3. PMC 6746994. PMID 31529486.
Wiwanitkit, Viroj (2006). "Quantum chemical analysis of the deferiprone-iron binding reaction". International Journal of Nanomedicine. 1 (1): 111–3. doi:10.2147/nano.2006.1.1.111. PMC 2426763. PMID 17722270.
Wiwanitkit, Viroj (2006). "Quantum Chemical Analysis of the Deferiprone-Iron Binding Reaction". International Journal of Nanomedicine. 1 (1): 111–3. doi:10.2147/nano.2006.1.1.111. PMC 2426763. PMID 17722270.
Samavat A, Modell B; Modell (November 2004). "Iranian national thalassaemia screening programme". BMJ (Clinical Research Ed.). 329 (7475): 1134–7. doi:10.1136/bmj.329.7475.1134. PMC 527686. PMID 15539666.
Sabloff, M; Chandy, M; Wang, Z; Logan, BR; Ghavamzadeh, A; Li, CK; Irfan, SM; Bredeson, CN; et al. (2011). "HLA-matched sibling bone marrow transplantation for β-thalassemia major". Blood. 117 (5): 1745–50. doi:10.1182/blood-2010-09-306829. PMC 3056598. PMID 21119108.
Sodani, P; Isgrò, A; Gaziev, J; Paciaroni, K; Marziali, M; Simone, MD; Roveda, A; De Angelis, G; et al. (2011). "T cell-depleted hla-haploidentical stem cell transplantation in thalassemia young patients". Pediatric Reports. 3 (Suppl 2): e13. doi:10.4081/pr.2011.s2.e13. PMC 3206538. PMID 22053275.
Negre, Olivier; Eggimann, Anne-Virginie; Beuzard, Yves; Ribeil, Jean-Antoine; Bourget, Philippe; Borwornpinyo, Suparerk; Hongeng, Suradej; Hacein-Bey, Salima; Cavazzana, Marina; Leboulch, Philippe; Payen, Emmanuel (February 2016). "Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the β – Gene". Human Gene Therapy. 27 (2): 148–165. doi:10.1089/hum.2016.007. PMC 4779296. PMID 26886832.

nhlbi.nih.gov

"How Are Thalassemias Treated?". National Heat, Lung and Blood institute. Retrieved March 2, 2013.

npr.org

Stein R (31 October 2023). "FDA advisers see no roadblocks for gene-editing treatment for sickle cell disease". NPR. Archived from the original on 4 December 2023. Retrieved 4 December 2023.

semanticscholar.org

api.semanticscholar.org

Pennell, D. J.; Berdoukas, V; Karagiorga, M; Ladis, V; Piga, A; Aessopos, A; Gotsis, ED; Tanner, MA; et al. (2006). "Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis". Blood. 107 (9): 3738–44. doi:10.1182/blood-2005-07-2948. PMID 16352815. S2CID 6802958.
Jin, Haiyan; Terai, Shuji; Sakaida, Isao (2007). "The iron chelator deferoxamine causes activated hepatic stellate cells to become quiescent and to undergo apoptosis". Journal of Gastroenterology. 42 (6): 475–84. doi:10.1007/s00535-007-2020-5. PMID 17671763. S2CID 34700148.
Kattamis, Antonis (2005). "Combined therapy with deferoxamine and deferiprone". Annals of the New York Academy of Sciences. 1054 (1): 175–82. Bibcode:2005NYASA1054..175K. doi:10.1196/annals.1345.020. PMID 16339663. S2CID 29566007.
Galanello, R.; Campus, S. (2009). "Deferiprone Chelation Therapy for Thalassemia Major". Acta Haematologica. 122 (2–3): 155–64. doi:10.1159/000243800. PMID 19907153. S2CID 31161087.
Heli, Hossein; Mirtorabi, Siamak; Karimian, Khashayar (2011). "Advances in iron chelation: An update". Expert Opinion on Therapeutic Patents. 21 (6): 819–56. doi:10.1517/13543776.2011.569493. PMID 21449664. S2CID 41639654.
Nisbet-Brown, Eric; Olivieri, Nancy F; Giardina, Patricia J; Grady, Robert W; Neufeld, Ellis J; Séchaud, Romain; Krebs-Brown, Axel J; Anderson, Judith R; et al. (2003). "Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: A randomised, double-blind, placebo-controlled, dose-escalation trial". The Lancet. 361 (9369): 1597–602. doi:10.1016/S0140-6736(03)13309-0. PMID 12747879. S2CID 12396225.
Tesoriere, L.; Allegra, M.; Butera, D.; Gentile, C.; Livrea, M. A. (2006). "Cytoprotective effects of the antioxidant phytochemical indicaxanthin in β-thalassemia red blood cells". Free Radical Research. 40 (7): 753–61. doi:10.1080/10715760600554228. PMID 16984002. S2CID 25837703.
Leung TN, Lau TK, Chung TKh; Lau; Chung (April 2005). "Thalassaemia screening in pregnancy". Current Opinion in Obstetrics and Gynecology. 17 (2): 129–34. doi:10.1097/01.gco.0000162180.22984.a3. PMID 15758603. S2CID 41877258.{{cite journal}}: CS1 maint: multiple names: authors list (link)
Sheridan C (November 2023). "The world's first CRISPR therapy is approved: who will receive it?". Nature Biotechnology. 42 (1): 3–4. doi:10.1038/d41587-023-00016-6. PMID 37989785. S2CID 265350318. Archived from the original on 4 December 2023. Retrieved 4 December 2023.

web.archive.org

Claude Owen Burdick. "Separating Thalassemia Trait and Iron Deficiency by Simple Inspection". American Society for Clinical Pathology. Archived from the original on 22 September 2014. Retrieved 27 September 2011.
Spanish Baby Engineered To Cure Brother
"Zynteglo EPAR". European Medicines Agency (EMA). 25 March 2019. Archived from the original on 16 August 2019. Retrieved 16 August 2019. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Zynteglo". U.S. Food and Drug Administration. 17 August 2022. Archived from the original on 26 August 2022. Retrieved 26 August 2022.
"FDA Approves First Cell-Based Gene Therapy to Treat Adult and Pediatric Patients with Beta-thalassemia Who Require Regular Blood Transfusions". U.S. Food and Drug Administration (FDA) (Press release). 17 August 2022. Archived from the original on 21 August 2022. Retrieved 20 August 2022. This article incorporates text from this source, which is in the public domain.
Stein R (31 October 2023). "FDA advisers see no roadblocks for gene-editing treatment for sickle cell disease". NPR. Archived from the original on 4 December 2023. Retrieved 4 December 2023.
"MHRA authorises world-first gene therapy that aims to cure sickle-cell disease and transfusion-dependent β-thalassemia". Medicines and Healthcare products Regulatory Agency (MHRA) (Press release). 16 November 2023. Archived from the original on 25 November 2023. Retrieved 8 December 2023.
Sheridan C (November 2023). "The world's first CRISPR therapy is approved: who will receive it?". Nature Biotechnology. 42 (1): 3–4. doi:10.1038/d41587-023-00016-6. PMID 37989785. S2CID 265350318. Archived from the original on 4 December 2023. Retrieved 4 December 2023.
"Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, Casgevy (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia" (Press release). Vertex Pharmaceuticals. 16 November 2023. Archived from the original on 22 November 2023. Retrieved 9 December 2023 – via Business Wire.
"FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease". U.S. Food and Drug Administration (FDA). 8 December 2023. Archived from the original on 8 December 2023. Retrieved 8 December 2023. This article incorporates text from this source, which is in the public domain.
"Vertex and CRISPR Therapeutics Announce US FDA Approval of Casgevy (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease" (Press release). Vertex Pharmaceuticals. 8 December 2023. Archived from the original on 9 December 2023. Retrieved 9 December 2023 – via Business Wire.